Minerva Neurosciences, Inc. (NasdaqCM: NERV)
Health Care · Biotechnology · US
$2.89
-9.12% today · +25.7% 1Y
Minerva Neurosciences, Inc. (NasdaqCM: NERV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $151.84M and employs 7 people.
Over the last twelve months the share price has gained 25.7%, trading between 2.24 and 12.46.
Tweenvest scores Minerva Neurosciences, Inc. across four factors: quality 48/100, value 73/100. Its strongest factor is value.
NERV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $151.84M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -14.44
- Dividend yield
- —
- Beta (5Y)
- -0.12
- 52-week high
- $12.46
- 52-week low
- $2.24
- Avg volume (3M)
- —
- Shares outstanding
- 47.75M
- Employees
- 7
- Next earnings
- —
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
- ISIN
- US6033802058
- Founded
- 2007
- Listed since
- Jul 1, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Mycenax Biotech Inc.TPEX: 4726 | $154.11M | NT$23.80 | +2.59% |
| Tiziana Life Sciences LtdNasdaqCM: TLSA | $153.88M | $1.09 | -8.40% |
| NovaBridge BiosciencesNasdaqGM: NBP | $153.12M | $1.32 | -5.38% |
| BioInvent International AB (publ)OM: BINV | $152.68M | Skr23.10 | -0.43% |
| Essex Bio-Technology LimitedSEHK: 1061 | $149.73M | HK$2.08 | -3.26% |
| Scancell Holdings plcAIM: SCLP | $149.18M | £0.09 | +0.54% |
| Molecular Partners AGSWX: MOLN | $148.00M | CHF3.21 | -3.60% |
| Actinogen Medical LimitedASX: ACW | $147.68M | AU$0.06 | +1.85% |
Figures last refreshed Oct 11, 2026.